[CAR-T Cells in solid tumours: present and future]

Adoptive cell therapy with CAR-T cells (Chimeric Antigen Receptor T-cells) genetically modifies T lymphocytes in such a way that they express a new receptor capable of targeting certain specific tumor antigens. This therapy showed impressive results in some hematological malignancies but still faces many hurdles in the treatment of solid tumours. Indeed, paucity of antigen targets, antigen heterogeneity, poor trafficking to the tumor site and the immunosuppressive tumour microenvironment are the main challenges in solid tumours. The rapid advancement of CARs technologies, coupled with a better understanding of the mechanisms of efficiency, toxicity and resistance, pave the way for the success of CAR-T cells in solid tumours.